An Open-label Clinical Study to Determine the Effect of Enhanced Absorption Formula (MB EnzymeProandreg;) on the Bioavailability of Whey Protein in Healthy Male Subjects
A. Trehan, M. Verma, Sameer Maheshwari, Tanyya Khanna, P. Kumari, Harinder Singh
{"title":"An Open-label Clinical Study to Determine the Effect of Enhanced Absorption Formula (MB EnzymeProandreg;) on the Bioavailability of Whey Protein in Healthy Male Subjects","authors":"A. Trehan, M. Verma, Sameer Maheshwari, Tanyya Khanna, P. Kumari, Harinder Singh","doi":"10.35248/2157-7110.20.11.820","DOIUrl":null,"url":null,"abstract":"Background: Several reports recommend that the dietary supplementation with Whey Protein (WP) in liquid form has been a popular choice for most of the individuals, especially athletes. Some product labels suggest a high serving size of 50 g for WP. Nevertheless, due to the limited endogenous digestive enzymes output and fast transit time, the average amount digested and absorbed may be approximately 15 g, thereby restricting protein bioavailability. The objective of this study was to find out whether MB EnzymePro®, a unique patent-pending Enhanced Absorption FormulaTM (EAF) of digestive proteases, significantly increases the digestion and absorption of WP, ultimately increasing bioavailability. The study also investigated its usefulness in significantly altering nitrogen (N2) balance and C-Reactive Protein (CRP) levels. Methods: An open-label, three-period, crossover, an oral bioavailability study was performed in healthy male subjects under fasting conditions. The study was carried out as per the Institutional Ethics Committee (IEC) approved study protocol and was registered with Clinical Trials Registry-India (CTRI). The study involved twenty-four subjects (age 20-36 years, BMI 20.0-24.0 kg/m2). A single dose of 50 g of WP alone (control), with one capsule (treatment A) and two capsules (treatment B) of MB EnzymePro® was administered to each group comprising 8 subjects. Blood samples were collected at specific time points up to 4 h for amino acid profile and CRP analysis. A total of 17 amino acids were quantified. Urine was collected after up to 24 h for total N2 analysis. Pharmacokinetic parameters were calculated using Phoenix® WinNonlin®. Results: The overall protein bioavailability enhancement was more than 50% for WP with MB EnzymePro®. A significant increase of more than 60% in BCAAs was noticed in the MB EnzymePro® treatment. The N2 balance and CRP levels were significantly better in the treated groups than the control group. Conclusion: Compared with the control condition, a patent-pending blend of digestive proteases (MB EnzymePro®) increased the digestion and absorption (bioavailability) of WP with improved N2 balance and reduced CRP levels.","PeriodicalId":15727,"journal":{"name":"Journal of Food Processing and Technology","volume":"115 1","pages":"1-9"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Food Processing and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2157-7110.20.11.820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Several reports recommend that the dietary supplementation with Whey Protein (WP) in liquid form has been a popular choice for most of the individuals, especially athletes. Some product labels suggest a high serving size of 50 g for WP. Nevertheless, due to the limited endogenous digestive enzymes output and fast transit time, the average amount digested and absorbed may be approximately 15 g, thereby restricting protein bioavailability. The objective of this study was to find out whether MB EnzymePro®, a unique patent-pending Enhanced Absorption FormulaTM (EAF) of digestive proteases, significantly increases the digestion and absorption of WP, ultimately increasing bioavailability. The study also investigated its usefulness in significantly altering nitrogen (N2) balance and C-Reactive Protein (CRP) levels. Methods: An open-label, three-period, crossover, an oral bioavailability study was performed in healthy male subjects under fasting conditions. The study was carried out as per the Institutional Ethics Committee (IEC) approved study protocol and was registered with Clinical Trials Registry-India (CTRI). The study involved twenty-four subjects (age 20-36 years, BMI 20.0-24.0 kg/m2). A single dose of 50 g of WP alone (control), with one capsule (treatment A) and two capsules (treatment B) of MB EnzymePro® was administered to each group comprising 8 subjects. Blood samples were collected at specific time points up to 4 h for amino acid profile and CRP analysis. A total of 17 amino acids were quantified. Urine was collected after up to 24 h for total N2 analysis. Pharmacokinetic parameters were calculated using Phoenix® WinNonlin®. Results: The overall protein bioavailability enhancement was more than 50% for WP with MB EnzymePro®. A significant increase of more than 60% in BCAAs was noticed in the MB EnzymePro® treatment. The N2 balance and CRP levels were significantly better in the treated groups than the control group. Conclusion: Compared with the control condition, a patent-pending blend of digestive proteases (MB EnzymePro®) increased the digestion and absorption (bioavailability) of WP with improved N2 balance and reduced CRP levels.
背景:几份报告建议,液体形式的乳清蛋白(WP)膳食补充剂已成为大多数人,特别是运动员的流行选择。一些产品标签建议WP的最高食用量为50克。然而,由于内源性消化酶输出量有限,运输时间快,消化和吸收的平均量可能在15g左右,从而限制了蛋白质的生物利用度。本研究的目的是研究MB酶pro®,一种独特的正在申请专利的消化性蛋白酶增强吸收配方(EAF),是否能显著增加WP的消化和吸收,最终提高生物利用度。该研究还调查了其在显著改变氮(N2)平衡和c反应蛋白(CRP)水平方面的有效性。方法:对健康男性受试者在禁食条件下进行开放标签、三期、交叉、口服生物利用度研究。该研究是根据机构伦理委员会(IEC)批准的研究方案进行的,并在印度临床试验登记处(CTRI)注册。该研究涉及24名受试者(年龄20-36岁,BMI 20.0-24.0 kg/m2)。每组8名受试者给予单剂量50 g WP单独(对照),并给予MB酶pro®1粒胶囊(治疗A)和2粒胶囊(治疗B)。在特定时间点采集血样,最长可达4小时,用于氨基酸谱和CRP分析。共测定了17种氨基酸。24小时后收集尿液进行总氮分析。使用Phoenix®WinNonlin®计算药代动力学参数。结果:添加MB酶pro®后,蛋白的总体生物利用度提高50%以上。在MB酶pro®治疗中,BCAAs显著增加60%以上。治疗组N2平衡和CRP水平明显优于对照组。结论:与对照条件相比,正在申请专利的消化蛋白酶(MB酶pro®)混合物增加了WP的消化和吸收(生物利用度),改善了N2平衡,降低了CRP水平。